Literature DB >> 8837878

Are there alternative avian influenza viruses for generation of stable attenuated avian-human influenza A reassortant viruses?

K Subbarao1, R G Webster, Y Kawaoka, B R Murphy.   

Abstract

The present study evaluated gull influenza A viruses as donors of attenuating genes for the production of live, attenuated influenza A H1N1 and H3N2 avian-human (ah) reassortant viruses for use as vaccines to prevent disease due to influenza A viruses in humans. The previously evaluated duck influenza A viruses were abandoned as donors of attenuating avian influenza virus genes because clinical evaluation of H1N1 and H3N2 ah reassortant virus vaccines derived from duck viruses documented residual virulence of H1N1 reassortants for seronegative infants and young children. Gull influenza A viruses occupy an independent ecologic niche and are rarely isolated from species other than gulls. The possibility of using gull influenza A viruses as donors of internal gene segments in ah reassortant viruses was evaluated in the present study using three different gull viruses and three human influenza A viruses. Gull-human H3N2 reassortant influenza A viruses with the desired 6-2 genotype (six internal avian influenza virus genes and the two human influenza virus surface glycoprotein genes) were readily generated and were found to be attenuated for squirrel monkeys and chimpanzees. However, ah reassortant viruses with gull and human influenza A H1N1 genes were difficult to generate, and reassortants that had the desired genotype of six gull virus genes with human influenza A H1 and N1 genes were not isolated despite repeated attempts. The gull PB2, NP and NS genes were not present in any of the gull-human H1N1 reassortants generated. The under-representation of these three gene segments suggests that reassortants bearing one or more of these three gene segments might have reduced viability indicative of a functional incompatibility in their gene products. The difficulties encountered in the generation of a 6-2 gull-human H1N1 reassortant virus are sufficient to conclude that the gull influenza A viruses tested would not be useful as donors of sets of six internal genes to attenuate human influenza A viruses. This study also identifies influenza virus gene segments that appear to be incompatible for generation of reassortants. Elucidation of the molecular basis of this restriction may provide information on intergenic interactions involved in virion assembly or packaging.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8837878     DOI: 10.1016/0168-1702(95)00082-8

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  10 in total

Review 1.  The threat of avian influenza a (H5N1): part II: Clues to pathogenicity and pathology.

Authors:  Jindrich Cinatl; Martin Michaelis; Hans W Doerr
Journal:  Med Microbiol Immunol       Date:  2007-04-04       Impact factor: 3.402

Review 2.  The use of nonhuman primates in research on seasonal, pandemic and avian influenza, 1893-2014.

Authors:  A Sally Davis; Jeffery K Taubenberger; Mike Bray
Journal:  Antiviral Res       Date:  2015-03-05       Impact factor: 5.970

3.  Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.

Authors:  A C Schmidt; J M McAuliffe; B R Murphy; P L Collins
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

4.  Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone.

Authors:  Alexander C Schmidt; Daniel R Wenzke; Josephine M McAuliffe; Marisa St Claire; William R Elkins; Brian R Murphy; Peter L Collins
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

Review 5.  Current Opinion in LAIV: A Matter of Parent Virus Choice.

Authors:  Irina Kiseleva
Journal:  Int J Mol Sci       Date:  2022-06-19       Impact factor: 6.208

6.  Contribution of neuraminidase of influenza viruses to the sensitivity to sera inhibitors and reassortment efficiency.

Authors:  Irina Kiseleva; Natalie Larionova; Ekaterina Fedorova; Ekaterina Bazhenova; Irina Dubrovina; Irina Isakova-Sivak; Larisa Rudenko
Journal:  Open Microbiol J       Date:  2014-07-11

7.  Comparative safety, immunogenicity, and efficacy of several anti-H5N1 influenza experimental vaccines in a mouse and chicken models (Testing of killed and live H5 vaccine).

Authors:  Alexandra S Gambaryan; Natalia F Lomakina; Elizaveta Y Boravleva; Ekaterina A Kropotkina; Vadim V Mashin; Igor V Krasilnikov; Alexander I Klimov; Larisa G Rudenko
Journal:  Influenza Other Respir Viruses       Date:  2011-09-23       Impact factor: 4.380

8.  An avian live attenuated master backbone for potential use in epidemic and pandemic influenza vaccines.

Authors:  Danielle Hickman; Md Jaber Hossain; Haichen Song; Yonas Araya; Alicia Solórzano; Daniel R Perez
Journal:  J Gen Virol       Date:  2008-11       Impact factor: 3.891

9.  Principles underlying rational design of live attenuated influenza vaccines.

Authors:  Yo Han Jang; Baik-Lin Seong
Journal:  Clin Exp Vaccine Res       Date:  2012-07-31

Review 10.  Sialic acid tissue distribution and influenza virus tropism.

Authors:  Urban Kumlin; Sigvard Olofsson; Ken Dimock; Niklas Arnberg
Journal:  Influenza Other Respir Viruses       Date:  2008-09       Impact factor: 4.380

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.